Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;81(5):595-598.
doi: 10.1007/s40265-021-01483-4. Epub 2021 Mar 22.

Ansuvimab: First Approval

Arnold Lee  1
Affiliations
Review

Ansuvimab: First Approval

Arnold Lee. Drugs. 2021 Apr.

Abstract

Ansuvimab (ansuvimab-zykl; EBANGA™) is a human monoclonal antibody developed by Ridgeback Biotherapeutics, which binds to the glycoprotein on Zaire ebolavirus (Ebola virus) to block its entry into host cells. Ansuvimab has been recently approved in the USA for the treatment of infection caused by Z. ebolavirus in adult and paediatric patients, including in neonates born to a mother who is RT-PCR positive for Z. ebolavirus infection, following the results of the PALM phase II/III trial. This article summarizes the milestones in the development of ansuvimab leading to this first approval for the treatment of infections caused by Ebola virus in adults and paediatric patients.

PubMed Disclaimer

Conflict of interest statement

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Lee is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Figures

None
Key milestones in the development of ansuvimab for the treatment of Ebola virus infection. BLA Biologics License Application
See this image and copyright information in PMC

References

    1. US Food & Drug Administration. FDA approves treatment for Ebola virus [media release]. 21 Dec 2020. https://www.fda.gov/.
    1. Ridgeback Biotherapeutics. EBANGA (ansuvimab-zykl): US prescribing information. 2021. https://dailymed.nlm.nih.gov/. Accessed 28 Jan 2021.
    1. Corti D, Misasi J, Mulangu S, et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016;351(6279):1339–1342. doi: 10.1126/science.aad5224. - DOI - PubMed
    1. Ridgeback Biotherapeutics. Ridgeback Biotherapeutics LP announces the approval of Ebanga™ for Ebola [media release]. 22 Dec 2020. https://ridgebackbio.com/.
    1. Ridgeback Biotherapeutics. Ridgeback Biotherapeutics LP announces licensing of mAb114, an experimental Ebola treatment, from the National Institute of Allergy and Infectious Diseases [media release]. 13 Dec 2018. https://ridgebackbio.com/.

MeSH terms

LinkOut - more resources